NASDAQ:HARP Harpoon Therapeutics (HARP) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.01▼$23.0150-Day Range$22.34▼$23.0152-Week Range$3.11▼$23.21VolumeN/AAverage Volume1.52 million shsMarket Capitalization$389.61 millionP/E RatioN/ADividend YieldN/APrice Target$27.25 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends Get Harpoon Therapeutics alerts: Email Address Harpoon Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside18.4% Upside$27.25 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.49) to ($4.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.20 out of 5 starsMedical Sector794th out of 936 stocksBiotechnology Industry4th out of 11 stocks 2.2 Analyst's Opinion Consensus RatingHarpoon Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageHarpoon Therapeutics has received no research coverage in the past 90 days.Read more about Harpoon Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for HARP. Previous Next 0.0 Dividend Strength Dividend YieldHarpoon Therapeutics does not currently pay a dividend.Dividend GrowthHarpoon Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHarpoon Therapeutics has received a 76.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Harpoon Therapeutics is -0.61. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harpoon Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions74.01% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harpoon Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($1.49) to ($4.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harpoon Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarpoon Therapeutics has a P/B Ratio of 14.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Harpoon Therapeutics Stock (NASDAQ:HARP)Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma. Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential. Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.Written by Jeffrey Neal JohnsonRead More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here HARP Stock News HeadlinesMay 27, 2024 | forbes.comHarpoon Brewery And Life Is Good Want To Offer Fans A New Summer StyleMay 16, 2024 | msn.comAmgen Drug Wins US Approval for Type of Advanced Lung CancerJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 14, 2024 | forbes.comIs Johnson & Johnson Stock A Better Pick Over Merck?May 14, 2024 | markets.businessinsider.comViracta Therapeutics Appoints Faerm As CFOMay 8, 2024 | msn.comMerck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.April 25, 2024 | msn.comMerck raises 2024 profit forecast on surging sales of cancer drug KeytrudaMarch 16, 2024 | finance.yahoo.comHARP Apr 2024 20.000 putJuly 26, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."March 16, 2024 | finance.yahoo.comHARP Sep 2024 20.000 putMarch 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)March 12, 2024 | msn.comMerck completes acquisition of Harpoon TherapeuticsMarch 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)March 6, 2024 | msn.comHarpoon Therapeutics ticks higher amid Nasdaq delisting notice for sale to MerckFebruary 27, 2024 | msn.comCitigroup Downgrades Harpoon Therapeutics (HARP)February 26, 2024 | markets.businessinsider.comAnalyst Scoreboard: 4 Ratings For Harpoon TherapeuticsFebruary 24, 2024 | realmoney.thestreet.comHarpoon Therapeutics just downgraded at Citi, here's whyFebruary 23, 2024 | usnews.comFate of US Aid to Ukraine Package Discussed on Taiwan Trip, Lawmakers SaySee More Headlines Receive HARP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:HARP CUSIPN/A CIK1708493 Webwww.harpoontx.com Phone(650) 443-7400FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Target$27.25 High Stock Price Target$40.00 Low Stock Price Target$23.00 Potential Upside/Downside+18.4%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($8.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,730,000.00 Net Margins-81.68% Pretax Margin-81.67% Return on Equity-893.55% Return on Assets-45.98% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$37.34 million Price / Sales10.43 Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book14.12Miscellaneous Outstanding Shares16,932,000Free Float14,054,000Market Cap$389.61 million OptionableOptionable Beta2.11 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Julie M. Eastland M.B.A. (Age 60)President, CEO, Secretary & Director Comp: $910.77kDr. Luke N. Walker M.D. (Age 52)Chief Medical Officer Comp: $424.43kMr. Michael Eric Faerm (Age 57)Interim Chief Financial Officer Dr. Chatan Charan Ph.D.Senior Vice President of Product Development, Technical & Manufacturing OperationsMr. James B. Bucher J.D. (Age 58)Chief Legal Officer Ms. Wendy ChangChief People OfficerDr. Banmeet Anand Ph.D.Senior Vice President of Translational MedicineMr. Haibo WangSenior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsNektar TherapeuticsNASDAQ:NKTRbluebird bioNASDAQ:BLUECytomX TherapeuticsNASDAQ:CTMXLianBioNASDAQ:LIANPHAXIAM TherapeuticsNASDAQ:PHXMView All CompetitorsInsidersMerck & Co., Inc.Bought 21,397,205 shares on 3/11/2024Total: $492.14 M ($23.00/share)View All Insider Transactions HARP Stock Analysis - Frequently Asked Questions How were Harpoon Therapeutics' earnings last quarter? Harpoon Therapeutics, Inc. (NASDAQ:HARP) issued its quarterly earnings results on Monday, March, 27th. The company reported ($5.50) earnings per share for the quarter, missing analysts' consensus estimates of ($4.70) by $0.80. The business had revenue of $4.09 million for the quarter, compared to analyst estimates of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 893.55% and a negative net margin of 81.68%. When did Harpoon Therapeutics' stock split? Shares of Harpoon Therapeutics reverse split on the morning of Tuesday, September 5th 2023. The 1-10 reverse split was announced on Tuesday, September 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO? 5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend. When did Harpoon Therapeutics IPO? Harpoon Therapeutics (HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers. What other stocks do shareholders of Harpoon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS) and Kaleido Biosciences (KLDO). This page (NASDAQ:HARP) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harpoon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
